« Back to Farmacia Journal 6/2022

DISORDERS OF PULMONARY FUNCTION IN TYPE 2 DIABETES MELLITUS PATIENTS WITH DIFFERENT TYPES OF ORAL HYPOGLYCEMIC MEDICATIONS: METFORMIN, METFORMIN PLUS THIAZOLIDINEDIONE AND METFORMIN PLUS SULFONYLUREA

RUA,A TARIQ ABDULSAIED 1*, AZZA SAJID JABBAR 2 ,TALIB KADHIM AKAR 3

1Al-Fayhaa Teaching Hospital, Basrah Health Directory, Basrah City, Iraq
2Department of Pharmacology and Toxicology, College of pharmacy, Basrah University, Basrah City, Iraq 3Department of Internal Medicine, College of Medicine, Basrah University, Basrah City, Iraq

Download Full Article PDF

Diabetes mellitus type 2 (DM2) is a chronic condition characterized by elevated blood glucose leading to organ dysfunction including the lung. In this study, we tried to determine the effects of hyperglycemia on lung functions and evaluate the role of certain oral antidiabetic medications in respiratory function changes. Two hundred and sixty individuals of both genders were enrolled in the study: 100 healthy individuals, and an age-matched group of 160 DM2 patients. Patients’ groups were further classified into 3 groups: (51) patients on metformin; (56) patients on metformin plus thiazolidinedione and (53) patients on metformin plus sulfonylurea. Clinical examination, electrocardiography, HbA1c, and pulmonary function parameters were estimated for all participants. Pulmonary function parameters significantly diminished (p < 0.05) in diabetic patients with increased restrictive disorder. Metformin plus sulfonylurea was more associated with decreased pulmonary function parameters with an odd ratio (OR: 2.999; at 95% confidence interval (CI): 1.006 - 8.937, (p > 0.05) than other medications. Pulmonary function parameters may act as a screening method to detect changes in diabetic lungs and manage pulmonary dysfunction, which was mostly restrictive. Assessments of pulmonary function may be useful to prescribe suitable medication, particularly for those with respiratory issues.